Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.
Cue Biopharma has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Cue Biopharma's investors include Cormorant Asset Management, Columbia Threadneedle Investments, MDB Capital Group.
Cue Biopharma is headquartered in Cambridge, United States.
Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.
Cue Biopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cue Biopharma — Funding & Investors." VCBacked, July 9, 2026, https://www.vcbacked.co/company/cue-biopharma. Accessed August 14, 2026.
VCBacked. (2026). Cue Biopharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cue-biopharma
{{cite web |title=Cue Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/cue-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated